We have a strong track record in process optimization and robust process development of peptide molecules. Our team is highly experienced in handling all forms of peptide synthesis viz. solid, solution or hybrid phase peptides at our R and D centers in Hyderabad and Bangalore.
We have a dedicated peptide lab to support peptide synthesis, downstream purification, isolation and lyophilization.
As one of the leading CDMO, we have a state-of-the-art analytical laboratory for impurity characterization and profiling based on spectral methods.
We have one of the largest facilities to manufacture high-throughput synthesis of a wide variety of standard and complex peptides. We can manufacture various types of peptide classes with linear peptides up to 40 AA, conjugates of peptides such as small molecules, lipids, carbohydrates, and PEG. Cost effective LPPS approach for small peptides or linkers. We have expertise in process optimization and robust development for commercial manufacturing.
Our advanced technology with modern infrastructure enables us to produce up to 2 kg of linear and branched chain peptides. We provide peptide manufacturing services from our state-of- the-art manufacturing site in Vizag. The site is inspected by major regulatory bodies such as the US FDA, MHRA, and PMDA.
For your clinical supplies and commercial manufacturing needs, we provide peptide manufacturing services from our state-of-the-art manufacturing sites in Visakhapatnam. Both these sites are inspected by major regulatory bodies such as USFDA, MHRA, PMDA etc. Our facilities are equipped with microwave assist technology, liberty pro automatic synthesizers, and fully automated ion exchange purification systems.
Extensive knowledge in developing & manufacturing hundreds of complex pharmaceutical products
Seamless integration from discovery to manufacturing
Capabilities across a wide range of peptide molecules
Large manufacturing capacities with automatic synthesizers
Rethink processes to ensure better quality in shorter timelines
Apply new science and technologies, to reduce costs or risk and add innovation
APRIL 24, 2023
Both natural and unnatural catastrophic events inflict negative consequences due to the ever-increasing interconnectedness of the global economy. Those consequences are certain to last for longer duration. e.g.; The Covid-19 pandemic is still having a negative impact on the global economy. Maintaining continuity is critical for all businesses, but perhaps no othe...Read More
Peptides are short chains of amino acids that are linked by peptide bonds. Several peptides linked together are called polypeptides. A protein contains one or more polypeptides. Therefore, proteins are long chains of amino acids held together by peptide bonds....Read More
Aurigene Pharmaceutical Services has a legacy of +20 years in developing and manufacturing compounds under cGMP. Our manufacturing plants are spread across 3 continents with facilities in India, UK, and Mexico. ...Read More
Introduction: Any new chemical entity (NCE) needs to undergo various stages of development such as preclinical and clinical trials before drug product is approved by regulatory agencies and available for patient. Formulations developed during early phases are simple formulations to enable phase appropriate studies like screening, dose ranging, toxicological and d...Read More
The reaction of b-chloroacrolein with 1 equiv of 2-aminophenol in DMF proceeds smoothly to afford 11-hydroxy derivative of chromenoquinoline in good yield. This single pot method allows for a rapid access to a variety of chromenoquinolines or oxepinoquinolines depending on the nature of b-chloroacrolein used. The structures were established by spectroscopic data ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.